影像学在非酒精性脂肪性肝病临床研究及实践中的地位

王屹

doi:10.3969/j.issn.1001-5256.2017.12.010

影像学在非酒精性脂肪性肝病临床研究及实践中的地位

DOI: 10.3969/j.issn.1001-5256.2017.12.010

王屹

北京大学人民医院放射科

详细信息

中图分类号: R445;R575.5;R816.5
计量
- 文章访问数: 2238
- HTML全文浏览量: 13
- PDF下载量: 436
- 被引次数: 0
出版历程
- 出版日期: 2017-12-20

Role of imaging techniques in clinical research and practice on nonalcoholic fatty liver disease

Wang Yi

摘要

摘要: 腹部超声(US)、计算机断层扫描(CT)和磁共振影像(MRI)均被用于非酒精性脂肪性肝病(NAFLD)的临床诊断和研究中。阐述了US、CT、MRI评价NAFLD的优势与局限性。与传统影像学检查相比,多参数定量MRI技术能够客观全面地评价NAFLD。脂肪质子密度(PDFF)被认为是脂肪肝诊断金标准并被应用于临床研究中。PDFF的实用性、可靠性、可转化性在成人及儿童的独立临床研究中通过多个MR扫描系统及应用软件被反复证实。磁共振弹性成像能够评价肝纤维化程度,且不受肝脂肪变性的影响。NAFLD肝脂肪沉积及纤维化均可在MRI检查中一站式测定,并在一定程度上成为替代肝穿刺的诊断方法。
- 非酒精性脂肪性肝病 /
- 超声检查 /
- 体层摄影术,螺旋计算机 /
- 磁共振成像
Abstract: Abdominal ultrasound ( US) , computed tomography ( CT) , and magnetic resonance imaging ( MRI) have been used in the clinical diagnosis and management of nonalcoholic fatty liver disease ( NAFLD) . This article elaborates on the advantages and limitations of US, CT, and MRI in the evaluation of NAFLD. Compared with conventional imaging examinations, multi-parametric quantitative MRI allows for comprehensive and objective evaluation of NAFLD. Proton density fat fraction ( PDFF) is considered the gold standard for the diagnosis of fatty liver disease and has been applied in clinical research. Independent clinical studies in adults and children have confirmed the practicability, reliability, and transformative quality of PDFF using various MRI scanning systems and software. Magnetic resonance elastography is used to evaluate the degree of liver fibrosis and is not affected by hepatic steatosis. In patients with NAFLD, MRI can measure hepatic fat deposition and fibrosis in a single examination and, to a certain degree, it can replace liver biopsy.
- nonalcoholic fatty liver disease /
- ultrasonography /
- tomography /
- spiral computed

HTML全文

参考文献(30)

[1]GAO X, FAN JG, Study Group of Liver and Metabolism, Chinese Society of Endocrinology.Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders:consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology[J].J Diabetes, 2013, 5 (4) :406-415.

[2]ABD EL-KADER SM, EL-DEN ASHMAWY EM.Non-alcoholic fatty liver disease:The diagnosis and management[J].World J Hepatol, 2015, 7 (6) :846-58.

[3]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology, 2012, 55 (6) :2005-2023.

[4]AHMED M.Non-alcoholic fatty liver disease in 2015[J].World J Hepatol, 2015, 7 (11) :1450-1459.

[5]MUSSO G, GAMBINO R, CASSADER M, et al.Meta-analysis:natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity[J].Ann Med, 2011, 43 (8) :617-649.

[6]BEDOSSA P, CARRAT F.Liver biopsy:the best, not the gold standard[J].J Hepatol, 2009, 50 (1) :1-3.

[7]RATZIU V, CHARLOTTE F, HEURTIER A, et al.Sampling variability of liver biopsy in nonalcoholic fatty liver disease[J].Gastroenterology, 2005, 128 (7) :1898-1906.

[8]BOHTE AE, van WERVEN JR, BIPAT S, et al.The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy:a meta-analysis[J].Eur Radiol, 2011, 21 (1) :87-97.

[9]PATEL UB, BROWN G, RUTTEN H, et al.Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer[J].Ann Surg Oncol, 2012, 19 (9) :2842-252.

[10]DOWMAN JK, TOMLINSON JW, NEWSOME PN.Systematic review:the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther, 2011, 33 (5) :525-540.

[11]MERKLE EM, NELSON RC.Dual gradient-echo in-phase and opposed-phase hepatic MR imaging:a useful tool for evaluating more than fatty infiltration or fatty sparing[J].Radiographics, 2006, 26 (5) :1409-1418.

[12]REEDER SB, HU HH, SIRLIN CB.Proton density fat-fraction:a standardized MR-based biomarker of tissue fat concentration[J].JMagn Reson Imaging, 2012, 36 (5) :1011-1014.

[13]REEDER SB, CRUITE I, HAMILTON G, et al.Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy[J].J Magn Reson Imaging, 2011, 34 (4) :spcone.

[14]HU HH, KIM HW, NAYAK KS, et al.Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans[J].Obesity (Silver Spring) , 2010, 18 (4) :841-847.

[15]MEISAMY S, HINES CD, HAMILTON G, et al.Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat:blinded comparison with MR spectroscopy[J].Radiology, 2011, 258 (3) :767-775.

[16]REEDER SB.Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis[J].Hepatology, 2013, 58 (6) :1877-1880.

[17]SCHWIMMER JB, MIDDLETON MS, BEHLING C, et al.Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease[J].Hepatology, 2015, 61 (6) :887-895.

[18]BANNAS P, KRAMER H, HERNANDO D, et al.Quantitative magnetic resonance imaging of hepatic steatosis:Validation in ex vivo human livers[J].Hepatology, 2015, 62 (5) :1444-1455.

[19]DOYCHEVA I, CUI J, NGUYEN P, et al.Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE[J].Aliment Pharmacol Ther, 2016, 43 (1) :83-95.

[20]ARULANANDAN A, ANG B, BETTENCOURT R, et al.Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis[J].Clin Gastroenterol Hepatol, 2015, 13 (8) :1513-1520.e1.

[21]LOOMBA R, SIRLIN CB, ANG B, et al.Ezetimibe for the treatment of nonalcoholic steatohepatitis:assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial) [J].Hepatology, 2015, 61 (4) :1239-1250.

[22]LE TA, CHEN J, CHANGCHIEN C, et al.Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis:a randomized controlled trial[J].Hepatology, 2012, 56 (3) :922-932.

[23]NOUREDDIN M, LAM J, PETERSON MR, et al.Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials[J].Hepatology, 2013, 58 (6) :1930-1940.

[24]WONG VW, VERGNIOL J, WONG GL, et al.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease[J].Hepatology, 2010, 51 (2) :454-462.

[25]YIN M, TALWALKAR JA, GLASER KJ, et al.A preliminary assessment of hepatic fibrosis with magnetic resonance elastography[J].Clin Gastrenterol Hepatol, 2007, 5 (10) :1207-1213.e2.

[26]IIJIMA H, MORIYASU F, TSUCHIYA K, et al.Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis[J].Hepatol Res, 2007, 37 (9) :722-730.

[27]VERLOH N, UTPATEL K, HAIMERL M, et al.Liver fibrosis and Gd-EOB-DTPA-enhanced MRI:a histopathologic correlation[J].Sci Rep, 2015, 5:15408.

[28]SAITO K, LEDSAM J, SOURBRON S, et al.Measuring hepatic functional reserve using low temporal resolution Gd-EOB-DTPAdynamic contrast-enhanced MRI:a preliminary study comparing galactosyl human serum albumin scintigraphy with indocyanine green retention[J].Eur Radiol, 2014, 24 (1) :112-119.

[29]CHO CS, CURRAN S, SCHWARTZ LH, et al.Preoperative radiographic assessment of hepatic steatosis with histologic correlation[J].J Am Coll Surg, 2008, 206 (3) :480-488.

[30]HAIMERL M, VERLOH N, ZEMAN F, et al.Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI[J].PLo S One, 2013, 8 (12) :e85658.

施引文献

资源附件(0)

访问统计